title: Efficacy of TCH/TEC neoadjuvant chemotherapy for the treatment of HER-2-overexpressing breast cancer.
abstract: The aim of the present study was to observe the efficacy of neoadjuvant trastuzumab combined with docetaxel and carboplatin (TCH), and docetaxel, epirubicin and cyclophosphamide (TEC) chemotherapy in human epidermal growth factor receptor-2 (HER-2)-overexpressing breast cancer. The total cohort of 64 cases of HER-2-overexpressing breast cancer patients was divided into two groups according to their treatment preferences: The TCH group, consisting of 39 patients, and the TEC group, consisting of 25 patients. The neoadjuvant chemotherapy was continued for six cycles prior to comparison of the treatment efficacy. The TCG and TEC groups exhibited an overall response rate of 94.9 and 72.0% (37/39 and 18/25 cases; P<0.05), respectively, and a pathological complete response (pCR; defined as the presence of no invasive orin situresidual tumors in the breast) rate of 69.2 and 32.0% (27/39 and 8/25 cases; P<0.05), respectively. Furthermore, no significant differences were identified between the two groups of patients in terms of adverse reactions, such as cardiac dysfunction, bone marrow suppression and liver function impairment. In the present study, the treatment of HER-2-overexpressing breast cancer patients with TCH neoadjuvant chemotherapy demonstrated more favorable efficacy and a higher pCR rate when compared with the TEC-treated group.
authors: Center for Breast Disease Diagnosis and Treatment, The Second People's Hospital of Shenzhen, Shenzhen, Guangdong 518035, P.R. China.
authors: Weicai
authors: W
authors: Chen
authors: Center for Breast Disease Diagnosis and Treatment, The Second People's Hospital of Shenzhen, Shenzhen, Guangdong 518035, P.R. China.
authors: Jinsong
authors: J
authors: He
authors: Center for Breast Disease Diagnosis and Treatment, The Second People's Hospital of Shenzhen, Shenzhen, Guangdong 518035, P.R. China.
authors: Shufen
authors: S
authors: Song
authors: Center for Breast Disease Diagnosis and Treatment, The Second People's Hospital of Shenzhen, Shenzhen, Guangdong 518035, P.R. China.
authors: Min
authors: M
authors: Wang
authors: Center for Breast Disease Diagnosis and Treatment, The Second People's Hospital of Shenzhen, Shenzhen, Guangdong 518035, P.R. China.
authors: Huisheng
authors: H
authors: Wu
authors: Center for Breast Disease Diagnosis and Treatment, The Second People's Hospital of Shenzhen, Shenzhen, Guangdong 518035, P.R. China.
authors: Xianming
authors: X
authors: Wang
keywords: breast cancer; chemotherapy; human epidermal growth factor receptor-2 overexpression; neoadjuvant